Intracellular delivery of antibodies by chimeric Sesbania mosaic virus (SeMV) virus like particles

被引：37

作者：

Abraham, Ambily ^{[1
]}

Natraj, Usha ^{[1
]}

Karande, Anjali A. ^{[1
,2
]}

Gulati, Ashutosh ^{[2
]}

Murthy, Mathur R. N. ^{[2
]}

Murugesan, Sathyabalan ^{[3
]}

Mukunda, Pavithra ^{[3
]}

Savithri, Handanahal S. ^{[1
]}

机构：

[1] Indian Inst Sci, Dept Chem, Bangalore, Karnataka, India

[2] Indian Inst Sci, Mol Biophys Unit, Bangalore, Karnataka, India

[3] Theramyt Novobiol Pvt Ltd, Bangalore, Karnataka, India

来源：

SCIENTIFIC REPORTS | 2016年 / 6卷

关键词：

VIRAL NANOPARTICLES; PROTEIN-A; MONOCLONAL-ANTIBODIES; STAPHYLOCOCCUS-AUREUS; IN-VITRO; THERAPY; CANCER; CELLS; TRASTUZUMAB; FRAGMENT;

D O I：

10.1038/srep21803

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The therapeutic potential of antibodies has not been fully exploited as they fail to cross cell membrane. In this article, we have tested the possibility of using plant virus based nanoparticles for intracellular delivery of antibodies. For this purpose, Sesbania mosaic virus coat protein (CP) was genetically engineered with the B domain of Staphylococcus aureus protein A (SpA) at the beta H-beta I loop, to generate SeMV loop B (SLB), which self-assembled to virus like particles (VLPs) with 43 times higher affinity towards antibodies. CP and SLB could internalize into various types of mammalian cells and SLB could efficiently deliver three different monoclonal antibodies-D6F10 (targeting abrin), anti-a-tubulin (targeting intracellular tubulin) and Herclon (against HER2 receptor) inside the cells. Such a mode of delivery was much more effective than antibodies alone treatment. These results highlight the potential of SLB as a universal nanocarrier for intracellular delivery of antibodies.

引用

页数：12

共 48 条

[1] Differential Uptake of Chemically Modified Cowpea Mosaic Virus Nanoparticles in Macrophage Subpopulations Present in Inflammatory and Tumor Microenvironments
Agrawal, Arpita
Manchester, Marianne
[J]. BIOMACROMOLECULES, 2012, 13 (10) : 3320 - 3326
[2] Albanell J, 1999, DRUGS TODAY, V35, P931
[3] Albanell J, 2003, ADV EXP MED BIOL, V532, P253
[4] Antibody-Conjugated Nanoparticles for Biomedical Applications
Arruebo, Manuel
Valladares, Monica
Gonzalez-Fernandez, Africa
[J]. JOURNAL OF NANOMATERIALS, 2009, 2009
[5] Mechanistic Insights into the Neutralization of Cytotoxic Abrin by the Monoclonal Antibody D6F10
Bagaria, Shradha
Ponnalagu, Devasena
Bisht, Shveta
Karande, Anjali A.
[J]. PLOS ONE, 2013, 8 (07):
[6] STRUCTURE OF SESBANIA MOSAIC-VIRUS AT 3 ANGSTROM RESOLUTION
BHUVANESHWARI, M
SUBRAMANYA, HS
GOPINATH, K
SAVITHRI, HS
NAYUDU, MV
MURTHY, MRN
[J]. STRUCTURE, 1995, 3 (10) : 1021 - 1030
[7] Hydrazone Ligation Strategy to Assemble Multifunctional Viral Nanoparticles for Cell Imaging and Tumor Targeting
Brunel, Florence M.
Lewis, John D.
Destito, Giuseppe
Steinmetz, Nicole F.
Manchester, Marianne
Stuhlmann, Heidi
Dawson, Philip E.
[J]. NANO LETTERS, 2010, 10 (03) : 1093 - 1097
[8] CHAKRABARTI R, 1989, J BIOL CHEM, V264, P15494
[9] Therapeutic antibodies: successes, limitations and hopes for the future
Chames, Patrick
Van Regenmortel, Marc
Weiss, Etienne
Baty, Daniel
[J]. BRITISH JOURNAL OF PHARMACOLOGY, 2009, 157 (02) : 220 - 233
[10] Intracytoplasmic delivery of anionic proteins
Dalkara, D
Zuber, G
Behr, JP
[J]. MOLECULAR THERAPY, 2004, 9 (06) : 964 - 969

← 1 2 3 4 5 →